Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients

NCT04728139 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-01-13

No results posted yet for this study

Summary

* Evaluation Of Glypican 3 in serum of colorectal cancer patients .
* Correlation between Glypican 3 and clinicopathological characteristics of colorectal cancer .

Conditions

Interventions

DIAGNOSTIC_TEST

glypican 3

Assessment of glypican 3 presence in colorectal cancer patients using ELISA

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2024-09-30
Completion
2024-10-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04728139 on ClinicalTrials.gov